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Agitation in the ICU: part two. Life threatening agitation,
pathophysiology and effective treatment will appear in a future issue.
Introduction
The term ‘agitation’ describes a syndrome of excessive
motor activity, usually nonpurposeful and associated with
internal tension. For intensivists, agitation is not so much a
diagnosis, but a consequence of more fundamental etio-
logies that, when expressed, result in disquietude. Agitation
is important in the intensive care unit (ICU) because it can
alter the diagnosis and course of medical treatment. It can
cloud the etiology of underlying disease processes like a
smoke screen, making effective diagnosis difficult or
impossible. It may result in the inability of the patient to
cooperate with monitoring and therapeutics that requires
them to lie relatively still and quiet. Treatment of agitation
without considering underlying causation gives the false
impression of wellness when in reality end-organ damage
is occurring either as a result of agitation itself, or as a
result of exacerbation of underlying pathology.
Prior to the technological revolution in critical care medi-
cine, agitation was a relatively minor issue. Little could be
done for critically ill patients but make them as comfort-
able as possible and observe them for treatable decom-
pensations. Modern ICUs now have the potential to
return critically ill patients to productivity using techno-
logical advances in monitoring and closely titrated care,
effectively pinning the patient firmly to the bed with
tubes and appliances. As a result of our high-tech hemo-
dynamic monitoring and support devices, we have con-
ferred upon the already hemodynamically unstable
patient new kinds of stress we never had to deal with
before, and simplistic, symptomatic ‘shotgun’ sedation no
longer applies.
Anatomy of the cognitive centers
The temporal lobes and the Hesh gyrus receive auditory
information, modulate memory and language skills and
relay information to the cortex where cognitive judgments
are made and motor responses are integrated [1]. The
thalamus and basal ganglia act as relay stations between
lower centers and the cortex [2]. The brainstem enables
endurance and survival capabilities, modulating heart rate,
respiratory function and autonomic actions [3]. The pineal
gland is thought to modulate sleep–wake cycles [4]. The
hippocampal area including the mammillary bodies modu-
lates spatial memory formation, declarative memory,
working memory, memory indexing/storage, relating
expectancy to reality, and internal inhibition. Memory is
recorded in several parts of the brain at same time as
‘memory molecules’ for storage. These molecules are
modulated by limbic system, especially the mammillary
bodies. Bilateral hippocampal resection results in short-
term anterograde amnesia [5]. The hippocampus has
receptors for neurosteroids, both mineralocorticoid and
glucocorticoid. The mineralocorticoid receptors (high
affinity) are agonized by alderosterone, and antagonized
by spironolactone. The glucocorticoid receptors (low
affinity) are agonized by dexamethasone. There are no
known antagonists to glucocorticoid receptors. The locus
coeruleus is a small structure on the upper brainstem
under the fourth ventricle and is involved in the regula-
tion of wakefulness, attention and orientation [6] (Fig. 1).
Cerebral neuroreception
Receptors for neurotransmission are highly specialized
and recognize only specific transmitter chemicals [7].
Neurotransmission is accomplished by at least three kinds
of chemical transmitters (Table 1).
Acetylcholine achieves high concentrations in the basal
ganglia and account for the anticholinergic side effects of
medications such as tricyclic antidepressants. The neuro-
transmitter dopamine is particularly active in the midbrain
and limbic system, and the frontal lobes, modulating emo-
tional responses. In its simplified form, schizophrenia is
thought to be a result of increased dopamine neurotrans-
mission activity. Norepinephrine exerts a diffuse modu-
lating influence throughout the brain. Serotonin exerts a
thalamic influence and has been implicated in clinical
depression, sleep disorders, anxiety and pain. Other natu-
rally occurring substances can exert neurotransmission
ICU = intensive care unit; NMDA = N-methyl-D-aspartate; GABA, g-amino butyric acid; CNS = central nervous system; ACTH = corticotropin; CRF
= corticotropin-releasing factor; 5-HT = 5-hydroxytryptamine; REM = rapid eye movement; CCK = cholecystokinin.activity. Branch chained and aromatic amino acids may act
as false neurotransmitters during the encephalopathy of
liver failure [8]. Glutamate has been implicated in the
‘Chinese food syndrome’, where food with high amounts
of monosodium glutamate interfere with normal neuro-
transmission causing confusion [9]. Pain neurotransmis-
sion utilizes the opiate receptors found diffusely
throughout the limbic system and basal ganglia, frontal
and temporal cortex, thalamus, hypothalamus, midbrain
and spinal cord. Kappa and Mu opiate receptors do not
meet the typical criteria for neurotransmitters. They
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Table 1
Neurotransmission and chemical transmitters
Cholinergic Biogenic Amino acid
Acetylcholine Dopamine GABA
Norepinephrine Glycine
Serotonin Glutamate
Histamine Aspartate
GABA, g-amino butyric acid.
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Neuroreceptors are responsible for highly selective signal-
ing at synapses and also regulation. N-Methyl-D-aspartate
(NMDA) receptors occur within the cerebral cortex, cere-
bellum and hippocampus [11]. Depolarization of the
NMDA complex by glycine, the phencyclidine-like drugs
and aspartate results in the elaboration of excitatory neu-
rotransmitters that increase brain metabolic activity. The
NMDA receptor is unique in that it is permeable to both
sodium and calcium ions, so its electrical current is both
agonist- and voltage-dependent, and relatively long lived.
The g-amino butyric acid (GABA) receptors are inhibitory
complexes modulated by benzodiazepines, steroids and
barbiturates [12]. The GABA–benzodiazepine complex
hypothesis suggests that benzodiazepines attach to
GABA–benzodiazepine complexes in the brain, enhancing
chloride conduction resulting in the release of GABA.
This opens a chloride channel leading to inhibition of
neuronal excitation in the limbic system, resulting in anxio-
lysis, sedation or hypnosis, depending on dose. All neuro-
transmitter receptors can be ‘desensitized’ by a constant
flux of agonists and become less responsive. This mecha-
nism tends to prevent overstimulation at synapses by
excess released neurotransmitter. Receptors may also be
‘downregulated’, the absolute number of receptors
reduced as a response to the same kind of stimulus that
results in desensitization [13].
Neurotransmitters and anxiety
Stress usually produces an elevated sense of fear and
anxiety which causes increased norepinephrine turnover in
the limbic regions (hypocampus, amygdala, locus
coeruleus) and cerebral cortex [14]. Stress applied to labo-
ratory animals results in a decreased density of a2-adrener-
gic autoreceptors in the hippocampus and amygdala,
reflecting downregulation in response to elevated circulat-
ing endogenous circulating catecholamines, among other
desensitizing actions [15]. This causes an increase in
responsiveness of locus ceruleus neurons to excitatory
stimulation that is associated with a reduction in a2-adren-
ergic autoreceptor sensitivity [16]. This phenomenon may
be measured by assaying levels of platelet a2-adrenergic
autoreceptors. Yohimbine activates noradrenergic neurons
by blocking a2-adrenergic receptors and is thus anxiogenic.
Clonidine, an a2-agonist, seems to diminish anxiety symp-
toms by decreasing norepinephrine transmission [17].
Yohimbine blocks the effects of clonidine, and panic
attacks can be precipitated by its parenteral administration.
Behavioral sensitization to stress may also involve
‘memory imprinting’ alterations in noradrenergic function.
This is thought to be the mechanism of the Post Trau-
matic Stress Disorder originally recognized in Vietnam
veterans, but now recognized to be a sequelae to other
prolonged inordinately stressful events [18]. This syn-
drome is not uncommon following extremely stressful
ICU stays, especially if the patient experienced untreated
pain, anxiety or delirium [19]. The limbic and cortical
regions innervated by the locus coeruleus are those
thought to be involved in the elaboration of adaptive
responses to stress, eliciting increased responsiveness to
excitatory stimuli when previously experienced stimuli
occur again. Limited exposure to shock that does not
increase noradrenergic activity in control animals increases
norepinephrine release in animals previously exposed to
the same kind of stress [20].
Noradrenergic hyperfunction and agitation
Panic attacks, insomnia, accentuated startle, autonomic
hyperarousal and hypervigilence are characteristics of
noradrenergic hyperfunction [21]. Conditioned fear and
recollection of immobilization stress may be experienced
by patients who have experienced traumatic emergency
endotracheal intubation and mechanical ventilation in the
past. In ICU patients the sensitizing factor may result
from hemodynamic and metabolic decompensations as a
result of multisystem insufficiency [22]. In a panic attack,
the main symptom is dyspnea; the patient feels like he or
she wants to breathe but cannot. There are two kinds of
panic [23]: type one includes typical symptoms of
diaphoresis and tachycardia, and is effectively treated by
anxiolytic drugs including the benzodiazepines, especially
low dose continuous infusions of titratable ones like mida-
zolam and lorazepam; type two panic attacks are character-
ized by subjective dyspnea and hyperventilation. For this
variant of the syndrome, imiprimine tends to downregu-
late the brain’s ‘suffocation alarm system’ that promotes
the subjective sensation of dyspnea. It is thought that this
center is modulated by serotonin uptake neuroreceptors
[24]. Imiprimine, however, is not useful in the ICU
because of the long therapeutic lag period and because of
its many difficult-to-control side effects.
Symptoms of panic attacks are easily confused with those
of chronic heart failure, which a large population of ICU
patients are predisposed to. In addition, metabolic imbal-
ances associated with left heart failure and respiratory
failure may precipitate anxiety de novo. Patients controlled
on mechanical ventilation and chronic lung failure patients
may manifest acute increases in pCO2 resulting in further
catecholamine release, increasing agitation [25]. Agitated
patients tend to increase peripheral musculoskeletal
metabolism, increasing lactate and carbon dioxide produc-
tion [26]. Both lactate and increased CO2 are evolutionary
signals that danger is coming, prompting a responsive
response to stress and potential danger. Hypercapnea stim-
ulates the sympathetic centers resulting in tachycardia and
mild hypertension, and possibly promoting panic. Increas-
ed levels of lactate and CO2 enter the brain quickly and
can precipitate panic attacks [27]. During hyperventilation,
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reflexly, further limiting blood flow and O2 transport to the
brain which can result in mental confusion.
The treatment for heart failure radically differs from that of
panic attacks and the exact etiology of each disorder must
be accurately identified before treatment is begun. If the
panic episode is secondary to pump failure resulting in
tissue hypoxia and hypercarbia, establishing an airway and
ventilation will rapidly ameliorate hemodynamic instabil-
ity, resolving the agitation episode. However, if the patien-
t’s agitation results from a panic attack, aggressive airway,
ventilation and hemodynamic support will only make them
more agitated. In addition, effective treatment for the two
different kinds of panic are different in effectiveness and
complications. For type 1 panic, the ‘cost’ of benzodia-
zepines is sedation with possible ventilation impairment,
the potential for tolerance, rebound and withdrawal on
removal, all of which interfere with titration of ICU
ventilation and hemodynamic support. For type 2 panic,
the ‘cost’ of imiprimine therapy is the drug’s side effects,
usually worse than placebo for the first 4weeks of therapy,
then results improve. This period of time is too long to
benefit most ICU patients who suffer from relatively short
duration ailments, rapidly corrected by titrated life support.
Dopaminergic neurotransmitters and agitation
Acute stress increases dopamine release and metabolism in
a number of brain areas [28]. Dopaminergic innervation of
the medial and dorsolateral prefrontal cortex appears to be
particularly vulnerable to stress and relatively low intensity
levels of stress are capable of promoting significant
responses. The prefrontal dopaminergic neurons have a
number of higher functions including attention and
‘working’ memory, and the acquisition of coping patterns in
response to stress [29]. Amphetamines and cocaine agonize
these receptors and have a similar effect as stress, resulting
in symptoms such as anxiety, panic, hypervigilence, exag-
gerated startle reflexes and paranoia [30]. NMDA and
opiate receptors are plentiful in this area and stress-induced
innervation of the fronto-cortical neurons is prevented if
these receptors are selectively blocked. This increase of
dopamine from the dendrites of dopamine neurons may be
due to an alteration in GABA regulation of the dopamine
neurons. As with noradrenergic systems, single or repeated
exposures to stress potentiates the capacity of a subsequent
stressor to increase dopamine function in the forebrain
without altering basal dopamine turnover, suggesting that
the receptors have been hypersensitized [31].
Sensory and cognitive dissociations resulting from
dopaminergic hyperfunction produce a state of fear and
anxiety via direct anatomic connections from cortical brain
structures to the limbic system principally through
mesolimbic pathways [32]. It is thought that this disinhibi-
tion of mesolimbic dopamine neurons causes the bizarre
behavioral and cognitive symptoms experienced by
patients in schizophrenia and, by extension, with delirium
[33]. Delirium resulting from dopaminergic hyperfunction
is characterized by global disorders of cognition and wake-
fulness and by impairment of psychomotor behavior [34].
Major cognitive functions such as perception, deductive
reasoning, memory, attention and orientation are all glob-
ally disordered. Excessive motor activity frequently
accompanies severe cases of delirium and, when this
occurs, the resulting constellation of symptoms is called
‘agitated delirium’ [35]. Integrative brain failure in the
ICU environment is almost always associated with a
hemodynamic or metabolic decompensation, either intra-
or extracranial. The ICU environment provides a reposi-
tory of typical predisposing factors of a hemodynamic or
metabolic nature, including acute or chronic organic brain
vascular insufficiency, endocrine insufficiency, acute or
chronic cardiopulmonary decompensations, multiple organ-
system insufficiency, relative hypoxia, poor tissue perfu-
sion, multiple medications, and finally sleep–wake cycle
disruption caused by immobilization, anxiety and pain [36].
If excessive responses to dopaminergic systems contribute
to the aforementioned manifestations, the neuroleptic drugs
that decrease neurodopamine activity such as haloperidol
should alleviate some of the symptoms, particularly hyper-
vigilence and paranoia. Haloperidol is a butryphenone struc-
turally similar to droperidol with mechanisms of action
similar to piperazine-based phenothiazines [37]. Haloperidol
is a dopamine antagonist; benzodiazepines are GABA ago-
nists. Theoretically, there should be a synergistic relation-
ship between the two when used in a conjoined fashion. In
addition, butryphenones such as haloperidol suppress spon-
taneous movements and complex behavior patterns which
result from disharmonious brain function, with minimal
central nervous system (CNS) depressive effect [38]. There
is little or no ataxia, incoordination or dysarthria at ordinary
doses. Haloperidol appears to exert a diffuse depressive
effect by inhibiting dopaminergic receptors and reuptake of
neurodopamine in the subcortical, midbrain and brainstem
reticular formation [39]. A unique effect of haloperidol is a
relatively strong suppression of spontaneous musculoskele-
tal hyperactivity and behavior that results from hyper-
dopaminergic brain function without pronounced sedation
or hypotension [40]. Haloperidol produces less sedation than
other phenothiazines, with very little effect on heart rate,
blood pressure and respiration, and it appears to have a very
wide range between therapeutic doses and the dose which
precipitates extrapyramidal reactions [41]. It is thought that
haloperidol’s molecular structure is changed in some fashion
when given orally, increasing the possibility of extrapyrami-
dal reactions [42].
Opiate neurotransmitters and agitation
One of the fundamental behavioral effects of intense stress
is analgesia, resulting from the release of endogenous
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blocked by naloxone and shows cross tolerance to mor-
phine [44]. It is unknown whether the effects of stress on
endogenous opiates are related to the core clinical symp-
toms associated with anxiety and panic. The recent develop-
ment of novel drugs (termed peptoids) that mimic or block
neuropeptide function have opened up new clinical
approaches to a number of conditions [45]. Thus high effi-
cacy k opioid-receptor agonists such as CI-977 (enadoline)
have more potential for the treatment of pain-related
anxiety because the hemodynamic and ventilatory side
effects are fewer [46]. Peptoid antagonists appear to be rel-
atively free of side effects possibly because neuropeptide
systems are only activated under very selective conditions.
Peptoid agonists, on the other hand, can exert extremely
powerful actions on brain function and this may be related
to the key position neuropeptide receptors occupy in the
hierarchy of chemical communication in the brain.
Much evidence now exists that very complex neural con-
nections involving diverse areas of the nervous system
play a part in pain modulation. Pain signals may be edited
at the spinal cord level, in the periaqueductal gray matter
and brain stem raphe nuclei prior to reaching relays and
gating mechanisms in the thalamus on the way to the cere-
bral cortex [47]. The perception of noxious stimuli may
depend not only on peripheral stimulation and transmis-
sion, but also on modulation occurring in spinal cord and
higher structures. Accordingly, the subjective sensation of
pain can be effectively blocked at the brain level by nar-
cotic analgesics and also at the inflow tract level, explain-
ing the efficacy of spinal or epidural anesthesia [48].
Perceptions of pain from peripheral nocieceptors are inte-
grated and relayed via integrated afferent pathways from
the hypothalamus to the reticular activating system via the
reticular formation, beginning in the medulla and extend-
ing to the midbrain. This pathway links the brain with
perception of external events. Pain is a very potent activa-
tor of this system, and this explains the importance of the
elicitation of pain in the evaluation of consciousness [49].
Modulated signals ultimately reach the medulla oblongata
and the sympathetic outflow tracts of the spinal cord
leading to the pupils, heart, blood vessels, gastrointestinal
tract, pancreas, and adrenal medulla. Norepinephrine is
released from the postganglionic fibers into the target
organ and both epinephrine and norepinephrine are
released into the blood stream from the adrenal medulla.
The more intense the stimuli, the more pronounced the
response. The levels of norepinephrine generally increase
about that of epinephrine and the levels of 11- and 17-
hydroxycorticosteroids also increase. Painful stress has two
separate components: psychic and somatic; both of these
usually combine to stimulate the hypothalamus via a
common pathway [50]. In addition to promoting the
psychic symptom of anxiety, increased catecholamine
levels increase heart rate and myocardial contractility to
bolster cardiac output [51].
The analgesia and blunted emotional response to trauma
produced by release of endogenous opioids increase the
chances of survival after injury [52]. However, the emo-
tional response to opioids has been described as euphoric
[53]. The difference between suicide and adventure is
that the adventurer leaves a margin of safety. The nar-
rower the margin the more the adventure. It has been sug-
gested that precipitous increases in endogenous opiates
secondary to short-lived stress may explain the joys of
elective risk-taking behavior [54]. Opiates such as mor-
phine decrease stress-induced norepinephrine release in
the hippocampus, hypothalamus, thalamus and midbrain,
promoting anxiolysis and sedation as well as analgesia. In
addition to their analgesic and sedative effect, opiates
decrease the sympathetic discharge associated with the
pain of myocardial ischemia and pulmonary edema, and
thus exert a mild negative inotropic and chronotropic
effect. Opiates also exert a direct depressive effect on the
medullary respiration center. However, humoral responses
of patients in pain, such as hypertension and tachypnea
tend to counterbalance the side effects of narcotic anal-
gesics, such as hypotension from histamine release and
medullary ventilation center depression [55].
The hypothalamic–pituitary–adrenal axis and
agitation
Acute multifactorial stress increases corticotropin (ACTH)
and corticosterone levels. Stress-induced corticosterone
release may be involved in the central processing of stress-
related phenomena and subsequent learned behavior
responses [56]. The mechanism responsible for transient
stress induced hyperadrenocorticism and feedback resis-
tance may be a downregulation of glucocorticoid receptors
as a result of high circulating glucocorticoid levels elicited
by stress. This results in increased corticosterone secretion
and feedback resistance. Following termination of stress
and decreased circulating levels of glucocorticoids, the
number of receptors gradually return to normal and feed-
back sensitivity normalizes [57]. The effect of chronic stress
may also result in augmented corticosterone responses to a
previous exposure to stress [58,59]. Adrenalectomy has
been shown to increase the frequency of behavioral deficits
induced by intense stress [60]. This effect is reversed by
the administration of corticosteroids. Learning deficits pro-
duced by intense stress may be related to neurotoxic levels
of glucocorticoids to hippocampal neurons [61].
Corticotropin-releasing factor (CRF) is the hypothalamic
hypophysiotropic hormone that activates the pituitary–
adrenal axis [62]. CRF can also be a neurotransmitter in
other areas of the brain. CRF is anxiogenic when injected
intravenously, probably interacting with noradrenergic
neurons in these areas, increasing activity [63]. CRF may
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frontal cortex as well, a reaction similar to that promoted
by stress. Severe stress also produces increased levels of
CRF in the locus coeruleus, hippocampus and amygdala,
increasing emotional lability [64].
Autonomic hyperarousal and hypervigilence facilitate
appropriate rapid behavioral reaction to threat. Stress-
induced levels of cortisol may promote metabolic activa-
tion necessary for sustained physical demands necessary
to avoid further injury. Elevated catecholamine levels
increase heart rate and myocardial contractility to bolster
cardiac output as potential compensation for injury during
‘fight or flight’. Painful stimulation of somatic afferent
nerves is a potent activator of neuroendocrine changes.
Immediate inhibition of insulin production occurs coinci-
dentally with an increase in glucogon production, resulting
in increased blood sugar (hyperglycemia of stress), free
fatty acids, triglycerides and cholesterol to fuel possible
‘fight or flight’ [65]. Growth hormone and cortisol secre-
tion increase, providing an anti-inflammatory response for
potential trauma. Aldosterone production acts to conserve
salt and water, bolstering intravascular volume in case of
potential blood loss.
Previous studies with receptor antagonists suggested that
a1-adrenergic receptors were involved in defensive with-
drawal in rats [66]. However, b-adrenoreceptor antago-
nists may also be involved in stress-related responses
[67]. Propranolol pretreatment prevents the restraint-
induced changes in the behavior of mice after stressful
maze testing [68]. These results suggest the involvement
of CNS b-adrenergic receptors in stress-related behavioral
changes and suggest that b-adrenergic agonists exert anxi-
olytic effects that differ from those of the benzodia-
zepines. The activation of b-adrenoceptors may be an
important mechanism in the behavioral inhibition
induced by CRF, and that the neurochemical mecha-
nisms that underlie the ‘anxiogenic’ and the ‘activating’
behavioral effects of CRF are neuropharmacologically
distinct. The anxiolytic benzodiazepine alprazolam seems
to selectively decrease CRF concentration in the locus
coeruleus [69].
Clinical implications of neurotransmission and
agitation in the ICU
The acute behavioral responses brought about by the acti-
vation of neurotransmission-modulated humoral responses
by psychological and physical trauma represent evolution-
ary adaptive responses critical for survival in an uncertain
and potentially dangerous environment. These compen-
satory responses were presumably created at a time in the
universe when there were no high-tech surrogates for nat-
urally induced environmental stress. Patients in the hybrid
ICU environment undergo stress but no natural environ-
mental threat. The highly stressful environment of the
ICU may lead to a loss of orientation to time and place.
Monotonous sensory input such as repetitive and noisy
monitoring equipment, prolonged immobilization, espe-
cially with indwelling life support hardware, frequently
interrupted sleep patterns and social isolation eventually
contribute to the onset of brain dysfunction. However,
this high-tech habitat is capable of reversing multiple
organ-system insufficiency if the patient is able to tolerate
the inherent stress of the environment. Therefore, nor-
mally beneficial responses act to the patient’s detriment in
the artificial ICU environment and it is necessary to block
them as selectively as possible.
Ameliorating neurotramsission dysfunction in
the ICU
Blocking deleterious pain responses
The pain reflex is normally beneficial, allowing those
affected to recognize and avoid impending peril quickly.
However, when the pain cannot be avoided, the reflex
promotes decompensatory hemodynamic and metabolic
changes. An ideal treatment for pain would stop the
pain-induced reflex, calming the resultant numeral
response, with a minimum effect on other organ-system
functions (Table 2). This is not always possible with
currently utilized sedatives. Hypnotics such as the
benzodiazepines do not resolve pain, they merely super-
impose a layer of CNS depression which makes it harder
to diagnose where the pain is coming from and what
effect it is having on other organ systems. Antipsychotics
such as haloperidol do not have any analgesic effect, and
their side effects will predominate if given for analgesia,
adding more bizarre CNS symptoms to the already
agitated patient.
Morphine sulfate is the most widely used of all narcotic
analgesic/sedatives [70]. The drug is easily titrated by mul-
tiple routes and reversible with narcotic antagonists.
However, in addition to its sedative action, morphine has
profound effects on cardiac hemodynamics. Doses as small
as 0.1–0.2mg/kg can produce orthostatic hypotension in
normal subjects due to vasodilatation in the splanchnic
beds, decreasing preload and right heart filling pressures
[71]. This vasodilatory effect has been attributed to both
histamine release and direct effects from neural mediators
[72]. The respiratory depressive effect can be profound and
unpredictable. Fentanyl is a synthetic opiate 75–200-times
more potent than morphine, significantly more rapid acting
(1–2min) and with a shorter duration (30–40min) [73]. The
most used opiate, morphine, frequently promotes hypoten-
sion by a histamine vasodilating effect. Compared to mor-
phine, fentanyl promotes minimal histamine release and
exhibits significantly less effect on cardiac dynamics than
morphine. However, fentanyl’s affinity for fat can lead to its
accumulation during prolonged use, ultimately ‘leaching
out’ after discontinuation of the drug, limiting its long-term
use as a continuous infusion [74].
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agent that has almost pure analgesic activity. Sixty mil-
ligrams of ketorolac intramuscularly is 800-times as potent
as aspirin and approximately equal in analgesic effect to
10mg morphine sulfate [75]. However, ketorolac has sig-
nificantly less respiratory and hemodynamic effects than
morphine [76]. Ketorolac is useful in blocking the pain
reflex, and therefore the increased catecholamine response
in patients with marginal hemodynamic reserve. Incisional
pain prevents postoperative patients with upper midline
abdominal incisions from coughing effectively, causing a
significant decrease in forced expiratory volume, and com-
promising clearance of tracheal secretions. A ‘pure’ anal-
gesic may decrease risk of nosocomial pneumonia by
allowing patients to clear their secretions more effectively
with less risk of respiratory depression. ICU patients in
heart failure who must undergo painful procedures such as
invasive vascular catheterization, chest tube thoracostomy
or intra-aortic balloon placement also tolerate narcotic side
effects poorly and in whom the hemodynamic effects of a
catecholamine release would be decompensatory.
Anxiety and discomfort
The benzodiazepines have been the mainstay of ICU
anxiety treatment for a number of years because they offer
a relatively wide margin of safety from unwanted side
effects [77]. Benzodiazepines with short half lives are
especially useful when hour-to-hour titration is required in
unstable hemodynamics and for patients with coincident
liver disease [78]. Benzodiazepines attenuate stress-
induced increases in norepinephrine release in the hippo-
campus, cortex amygdaloid and locus coeruleus region,
effectively reducing conditioned fear and generalized
anxiety. Anterograde amnesia occurs almost immediately
after intravenous administration and usually persists for
20–40min after a single dose [79]. However, during
intense stress, these drugs may not be able to exert an
effective anxiolytic action except in hypnotic doses [80].
All of the benzodiazepines reduce ventilatory responses to
hypoxia when administered rapidly or in large doses [81].
Benzodiazepine toxicity usually results in an amplification
of their therapeutic effects, but rarely cardiac arrest unless
other cardioactive drugs have been given concurrently.
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Table 2
Treatment choices for anxiety in the intensive care unit
Benzodiazapines Central nervous system depressants with anterograde amnestic musculoskeletal relaxation and anxiolytic action.
Blunts the patient’s perception of distress. No analgesic activity.
Lorezapam Mild anxiolytic, slow acting, long acting, not titratable. Accumulates quickly when used in continuous infusion. Low
performance-high safety factor.
Midazolam Potent, titratable for 48h can be titrated to siut the sedation requirements of the individual. Moderate
performance-moderate safety.
Propofol Very potent, very titratable (up to 1week). Facilitates control of life threatening agitation. High performance, low
safety.
Neuroleptics Not sedatives. Treatment for true delerium, not anxiety or discomfort. Reorganizes brain chemistry at level of
dopamine.
Haloperidol Always used intravenously. Step up dosing required. Continuous infusion useful in selected patients.
Droperidol Similar to haloperidol except associated with frightening dreams that may require benzodiazepines for relief (thus
limiting its action).
Analgesics Stops pain reflex and offers comfort and mild anxiolysis.
Morphine sulfate Gold standard of analgesia/sedation. Multiple routes of delivery. Reversible. May cause hemodynamic respiratory
supression in patients with little reserve.
Fentanyl As effective as morphine but titratable in real time for 48h. No histamine release. Effectively titrates analgesia for
unstable patients.
Meperidine Not titratable. Causes hypotension, tachycardia, seizures and mental status changes in critically ill patients. 
Ketorolac Pure analgesia without sedation. Effective in stopping pain reflex for hemodynamically unstable patients.
Combination therapy Effective real time titration of both analgesia and sedation at the same time in the same patient.
Midazolam and fentanyl When separation of theraputic effect is desired, start with one and then add the other. The doses of both must be
reduced.
Speciality sedation agents Usually used as adjuncts to treatment for complicated patients.
Clonidine Offers analgesia, decreases adrenergic response. Side effects of bradycardia and dry mouth. Intravenous
formulation if possible.
Dexmetomidine In trial. A purer a2 action. More beneficial effects, fewer side effects. Will be useful in treating substance
withdrawal.
Reversal agents Titrating the effect of sedation or analgesia at the level of brain receptors.
Naloxone Rapid reversal of narcotics. Short acting. Should be used in continuous infusion to avoid complications of sudden
awakening.
Flumazenil Rapid reversal of benzodiazepines. Short acting. Should be used in continuous infusion to avoid complications of
sudden awakening.a2-Adrenoreceptors are located both centrally and periph-
erally. Their function is to inhibit norepinephrine release
from presynaptic junctions by several negative feedback
mechanisms, effectively suppressing neuronal firing and
norepinephrine secretion in all target effecter organs con-
taining  a2-receptors, including the central sympathetic
nervous system [82]. As a result, a2-adrenergic agonists
potently inhibit sympathoadrenal outflow, as evidenced
by the decreased levels of circulating norepinephrine and
the diminution of catecholamine metabolites in the urine.
a2-Agonists, which long ago established themselves as
antihypertensives, have also been found to possess intrin-
sic anxiolytic, sedative, analgesic, and antiemetic proper-
ties [83]. These attributes make them attractive for use in
the treatment of agitation and delirium associated with
noradrenergic hyperfunction [84]. a2-Agonists adminis-
tered concurrently with benzodiazepines or opiate anal-
gesics permit significantly decreased doses of these
sedative narcotics, minimizing side effects while maintain-
ing effective levels of sedation and analgesia [85].
Among clinically available a2-agonists, clonidine seems to
be the most selective. Clonidine is thought to act by com-
petitively binding opiate catecholaminergic receptors,
decreasing the amount of opiates required to get the same
sedative effect. As a consequence, respiratory depression,
hypotension, and other side effects of narcotic sedatives
are significantly attenuated, especially in hemodynami-
cally unstable patients [86]. Clonidine has been shown to
decrease the amount of anesthesia required to obtain
operative analgesia [87]. Clonidine has been effectively
used intrathecally for analgesia in terminal cancer patients
who had become tolerant to intrathecal morphine [88].
Clonidine has been extensively used on psychiatry wards
to attenuate drug withdrawal syndrome after chronic
benzodiazepine and alcohol use [89]. Clonidine has also
been proved to be effective in patients with panic dis-
orders due to its anxiolytic action and its ability to
decrease the brain noradrenergic neuronal hyperactivity.
Clonidine is almost completely absorbed after oral admin-
istration, but takes 60–90min to reach peak plasma con-
centration [90]. A large number of ICU patients are not
able to take the medication enterally, or, because of con-
current hemodynamic or metabolic instabilities, it is
absorbed erratically by that route. Drug delivery through a
transdermal patch takes much longer to reach effective
blood levels and a minimum of 2days to achieve a steady
state concentration, making this route ponderous for acute
care use [91]. Unfortunately, clonidine is not yet approved
for intravenous use in the USA, but intravenous adminis-
tration is common in Europe [92]. Careful titration of
intravenous clonidine as a supplement to analgesics or
sedatives in severe agitation syndromes in the critical care
patients is a new area of clinical investigation. Other
a2-agonists not currently used in clinical practice have
practical potential in the treatment of severe agitation and
delirium. The highly selective a2-agonist dexmedetomi-
dine has been shown to produce anxiolytic effects compa-
rable to benzodiazepines, but fewer negative effects on
hemodynamics. Dexmedetomidine is not yet available for
clinical use [93,94].
New horizons: selective serotonin and
cholecystokinin antagonists
Because of the clinical side effects and shortcomings of
the previous list of therapeutic medications, new agents
that act selectively on sensory pathways afferent to the
limbic system by decreasing the secretion of neurotrans-
mitters could be more selective in conditioned responses
without concurrent sedation and hypnosis. The serotonin
reuptake antagonists show promise as superselective anxio-
lytics, potentially valuable in the ICU where sedative side
effects directly affect hemodynamic, ventilatory and meta-
bolic stability during life support management [95].
Serotonin (5-hydroxytryptamine; 5-HT) is involved in
numerous physiological processes such as appetite, sleep,
pain, sexual behavior and temperature regulation. 5-HT
reuptake antagonists have been found effective in the
alleviation of depression and panic attacks, and are at
varying stages of clinical evaluation in the treatment of
obsessive–compulsive disorder, chronic pain, and bulimia
nervosa. Selective 5-HT receptor agonists and antagonists
show promise in the treatment of migraine, nausea and
vomiting, schizophrenia, anxiety, hypertension, and
Raynaud’s disease [96]. 5-HT interacts with multiple
brain 5-HT receptor subtypes to influence a wide range of
behaviors. Three main families of 5-HT receptors (5-HT1,
5-HT2 and 5-HT3) have been described. Several different
5-HT receptor subtypes (5-HT1A, 5-HT1C, 5-HT2 and
5-HT3) may produce anxiolytic effects; 5-HT1A and
5-HT2 receptors may be involved in the etiology of major
depression and the therapeutic effects of antidepressant
treatment; and 5-HT3 receptors have been linked to
reward mechanisms and cognitive processes [97]. Sero-
tonin1A agonists seem to be promising for anxiety and also
mixed anxiety–depression [98].
Buspirone, with a pharmacologic profile which distin-
guishes it from the benzodiazepines, appears to hold
future promise [99]. Buspirone does not act on the GABA
receptor; rather, its most salient interaction with neuro-
transmitter receptors occurs at the 5-HT1A receptor.
Because it lacks the anticonvulsant, sedative, and muscle-
relaxant properties associated with other anxiolytics, bus-
pirone has been termed ‘anxioselective’ [100]. Buspirone
does not have a euphoric effect and therefore has a low
potential for abuse. Pharmacologic studies on the molecu-
lar level indicate that buspirone interacts with dopamine
and 5-HT receptors. This action is supported by studies
focused on receptor binding, anatomical localization,
R42 Critical Care 1999, Vol 3 No 3biochemistry, neurophysiology, and animal behavior.
However, the lengthy ‘lag period’ before buspirone begins
to show pharmacologic activity limits its use in acute care
areas like the ICU.
The recognition that action at 5-HT1A receptors may be a
viable approach to the pharmacotherapy of anxiety is evi-
denced by the number of other agents of this class under
development by a number of pharmaceutical companies.
The cyclopyrrolone zopiclone functions as a selective hyp-
notic, extending the duration of slow wave sleep and con-
comitantly shortening the awake periods [101]. This slow
wave sleep inducing effect of zopiclone did not depress
rapid eye movement (REM) sleep and shows no rebound
of activity in wakefulness or REM sleep after treatment.
At the cortical level in rats, zopiclone increases the spec-
tral energy in the D band (0.5–4Hz). This rise in energy
can also reach the fast frequencies (b band: 12–16Hz).
This power spectrum is characteristic of a compound
having tranquilizing-hypnotic potential. The relatively
short duration of action of zopiclone minimizes the resid-
ual effects seen upon waking (drowsiness, impairment of
psychomotor performance). Binding is thought to occur at
the benzodiazepine receptor complex, or to a site closely
linked to this complex [102]. Although zopiclone exhibits
anticonvulsant, muscle relaxant and anxiolytic properties
in animals, its hypnotic effects are the most useful in
humans. In clinical trials, zopiclone improved sleep in
chronic insomniacs similarly to flurazepam [103]. Minimal
impairment of psychomotor skills and mental acuity have
been reported in the relatively small number of patients
studied to date [104].
Unlike zopiclone which exhibits a hypnotic action, suri-
clone is a novel benzodiazepine receptor ligand with
enhanced anxiolytic properties [105]. Although chemically
entirely different from the benzodiazepines, it acts as a
functional benzodiazepine agonist with very high affinity
for the benzodiazepine receptors. In studies, suriclone and
diazepam had a different side-effect profile; suriclone pro-
duced mainly dizziness, while diazepam caused sedation
[106]. This may reflect the fact that suriclone and benzo-
diazepines bind to distinct sites or different allosteric con-
formations of the benzodiazepine receptors. The drug,
when effective, has a duration of action between 6 and 8h.
There was no evidence of a rebound phenomenon. There
was, however, a rapid return to pretreatment level of
anxiety, which makes its use as a continuous, titratable
infusion attractive.
The role of cholecystokinin (CCK) receptors in the devel-
opment of anxiety is a new field of investigation [107].
CCK is an octapeptide normally synthesized in the gut, but
also with large concentrations in the brain where it acts as a
neurotransmitter. Central CCKergic neurotransmission has
been implicated in the genesis of negative emotions,
feeding disorders such as anorexia, nociception alterations,
movement disorders, schizophrenia, anxiety and panic dis-
orders [108]. The interaction of CCK with GABAergic
inhibitory neurotransmission, mediated probably through
CCK-B receptors, could be the neurochemical substrate for
anxious type of exploratory behavior. The brain cholecys-
tokinin-B/gastrin receptor (CCK-B/gastrin) has been impli-
cated in mediating anxiety, panic attacks, satiety, and the
perception of pain [109]. The isolation of rats for 7days
produced anxiogenic-like effect on their behavior and
increased the number of CCK receptors in the frontal
cortex without affecting benzodiazepine receptors [110].
CCK and benzodiazepine receptor binding characteristics
were analyzed in the brain tissue samples from 13 suicide
victims and 23 control cases. In the frontal cortex, signifi-
cantly higher apparent number of CCK receptors and affin-
ity constants were found in the series of suicide victims. The
results of this investigation suggest that CCKergic neuro-
transmission is linked to self-destructive behavior, probably
through its impact on anxiety and adaptational deficits [111].
The behavioral effects of an experimental selective CCK-B
receptor antagonist CI-988 were investigated in rodents. In
three rodent tests of anxiety (rat elevated X-maze, rat social
interaction test and mouse light–dark box), CI-988 produced
an anxiolytic-like action over a wide dose range. The magni-
tude of this effect was similar to that of chlordiazepoxide
[112]. In contrast, the selective CCK-A receptor antagonist
devazepide was inactive [113].
Central but not peripheral administration of the selective
CCK-B receptor agonist, pentagastrin, produced an anxio-
genic-like action [114]. The pentagastrin-induced anxiety
was dose-dependently antagonized by CI-988, whereas
devazepide was inactive. CI-988 did not interact with
alcohol or barbiturates. Thus, CI-988 appears to be an
anxioselective compound unlike benzodiazepines but the
anxiolytic-like action was dose-dependently antagonized
by flumazenil. The possible involvement of endogenous
CRF in the anxiogenic and pituitary–adrenal axis activat-
ing effects of CCK octapeptide sulfate ester (CCK8) was
investigated in rats [115]. The results strongly suggest that
the anxiogenic and hypothalamo–pituitary–adrenal acti-
vating effects of CCK8 are mediated via CRF [116].
Tetronothiodin is a novel CCK-B receptor antagonist pro-
duced from the fermentation broth of the NR0489a Strep-
tomyces species [117]. Tetronothiodin inhibited the
binding of CCK8 (C-terminal octapeptide of CCK) to rat
cerebral cortex membranes (CCK-B receptors), but did
not inhibit CCK8 binding to rat pancreatic membranes
(CCK-A receptors). This finding indicated tetronothiodin
was an antagonist of CCK-B receptors and may have use
as a superselective antianxiety agent. It is a useful tool for
investigating the pharmacological and physiological roles
of CCK-B receptors and has no clinical role as yet.
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